SIGA Pharmaceuticals Receives Research Grants.
NEW YORK--(BUSINESS WIRE)--Oct. 6, 1999--
SIGA SIGA Saskatchewan Indian Gaming Authority
SIGA Simplified Improved Gaussian Approximation
SIGA Special Interest Group in Andrology (ESHRE)
SIGA Silizium, Galvanik Und Abformung
SIGA Sunshine in Government Act of 1976 Pharmaceuticals, Inc. (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations
U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : SGPH) announced today that it has been awarded two research grants totaling $400,000. The grants will support antibiotic and strep throat Strep Throat Definition
Streptococcal sore throat, or strep throat as it is more commonly called, is an infection of the mucous membranes lining the pharynx. Sometimes the tonsils are also infected (tonsillitis). vaccine development programs at SIGA Research Labs, the Company's research and development facility. The grants were awarded by the Small Business Innovation Research Program (SBIR SBIR Small Business Innovation Research (program/grant)
SBIR Space Based Infra-Red
SBIR Speaker-Boundary Interference
SBIR Site Backsurface-referenced Ideal Plane/Range (silicon wafers) ) of the National Institutes of Health.
The first grant will support the Company's antibiotic discovery efforts. SIGA's antibiotics programs are aimed at "disarming" bacteria by interfering with the expression of bacterial surface proteins. Surface proteins are used by bacteria in the attachment to human tissue, the first step in the infection process. No existing antibiotics act through this mechanism.
The second grant will support the development of a subunit vaccine targeting strep throat based on the Company's proprietary antigen. Strep throat can be caused by more than 120 different types of group A streptococcus group A streptococcus
A common but virulent streptococcus that kills the tissue it infects and produces toxins that trigger a form of shock that affects the vital organs. , and SIGA's technology is based on a region of the streptococcus streptococcus (strĕp'təkŏk`əs), any of a group of gram-positive bacteria, genus Streptococcus, some of which cause disease. M protein that is common to the multiple types of the disease causing bacteria. SIGA is currently developing StrepImmune, a group A streptococcal streptococcal /strep·to·coc·cal/ (-kok´al) pertaining to or caused by a streptococcus.
Pertaining to any of the Streptococcus bacteria. vaccine candidate based on the Company's proprietary commensal commensal /com·men·sal/ (kom-men´sil)
1. living on or within another organism, and deriving benefit without harming or benefiting the host.
2. a parasite that causes no harm to the host. bacteria delivery system. The StrepImmune program is being developed through a collaboration with the National Institutes of Health. "The development of a subunit vaccine will complement our existing vaccine efforts and will provide us with a second vaccine candidate for commercial development," said Dennis Hruby, Ph.D., SIGA's Vice President for Research.
Group A streptococcal pharyngitis, or strep throat, is one of the most common childhood diseases, affecting approximately 10 million children in the United States each year and a comparable number in Europe. Ineffectively treated, this disease, for which there is no vaccine available, can progress to rheumatic fever, ultimately leading to cardiac damage.
"These grants are an important endorsement of the quality of the underlying science at SIGA Research Labs," said Joshua D. Schein, Ph.D, SIGA's Chief Executive Officer. "Importantly, these awards will assist the Company in its objective of making its biotechnology operations self-sufficient as we continue to explore alternative strategies to maximize shareholder value," he added.
This news release contains forward-looking statements that involve risk and uncertainties. The development of SIGA's products may differ materially from the Company's expectations. Among the factors that could result in a materially different outcome are the inherent uncertainties accompanying drug discovery, clinical trials and new product development.